GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children
NCT00886626 on ClinicalTrials.gov · last registry update 2012-10-29
A small phase 2 — 12 participants, against a typical 110. The sponsor logged completion for February 2011. Primary outcome, as filed: Change in Body Mass Index (BMI). exenatide is approved in the US, but not for obesity — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P2
- Drug
- exenatideBydureon, Byetta
- Sponsor
- University of Minnesota
- Sponsor type
- Other
- Enrollment
- 12
- Started
- 2009-05
- Primary completion
- 2011-02 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in Body Mass Index (BMI)
Conditions studied
Obesity, Morbid
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.